News | Radiation Therapy | April 29, 2016

Elekta MR-Guided Linear Accelerator Highlighted at ESTRO 35

Seven abstracts will be presented on experimental system in various tumor-site applications

April 29, 2016 — Elekta announced that its high-field MR-guided linear accelerator (MR-linac) platform will be the focal point of seven scientific presentations at ESTRO 35, the annual meeting of the European Society for Radiotherapy and Oncology. The meeting will take place April 29 – May 3, 2016, in Turin, Italy.

Elekta’s MR-linac integrates a state-of-the-art radiotherapy system and a high-field magnetic resonance imaging (MRI) scanner with sophisticated software that allows a physician to clearly see the patient’s anatomy in real time. The MR-linac is designed to improve targeting of tumor tissue while reducing exposure of normal tissue to radiation beams. It will allow physicians to precisely locate a tumor, as well as lock onto it during delivery, even when tumor tissue is moving during treatment or changes shape, location or size between treatment sessions.

At ESTRO 35, the potential of Elekta’s MR-linac will be discussed in the following sessions:

  • Abstract SP-0485: “MR-linac: Clinical Introduction”; Christopher Schultz, M.D., FACR, professor in the Department of Radiation Oncology at Froedert and Medical College of Wisconsin. May 2, 2:30 p.m. - 4 p.m. This presentation will discuss the integration of MR-linac into current radiation therapy (RT) practice, the structure of the Elekta MR-linac Consortium and its plans to provide a robust body of evidence to support optimal development of MR-linac technology; and
  • Abstract OC-0549: “The effects of magnetic field and real-time tumor tracking on lung stereotactic body radiotherapy”; Martin J. Menten, a doctoral candidate at The Institute for Cancer Research, London. May 2, 4:45 p.m. – 5:45 p.m. This study demonstrates that use of Elekta’s Monaco treatment planning software accounts for the effects of magnetic field during treatment planning and enables the design of clinically acceptable lung stereotactic body RT with a MR-linac. The data also show that the magnetic field does not compromise the ability of real-time tumor tracking to decrease dose exposure to healthy tissue.

“To evaluate the effect of the magnetic field and real-time tumor tracking, we modeled several dose-volume metrics and the amount of energy that would be delivered to patients with lung tumors,” explained Prof. Uwe Oelfke, MCCPM, FInstP, and head of the Joint Department of Physics at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust. “Real-time tumor tracking would allow us to maintain dose coverage of gross tumor volume while reducing the dose delivered, which decreased exposure to skin and healthy lung tissue. This was observed with and without the presence of the magnetic field, demonstrating that Monaco effectively addresses the challenge posed by the interaction of the MRI with the delivery of radiation therapy.”

Additional presentations include:

  • Abstract: OC-0075: “Impact of air around an ion chamber: solid water phantoms not suitable for dosimetry on an MR-linac”; S. Hackett, B. van Asselen, J. Wolthaus, J. Kok, S. Woodings, J. Lagendijk, B. Raaymakers; April 30, 10:45 – 11:45 a.m.;
  • Abstract: OC-0076: “Towards MR-Linac Dosimetry: B-Field Effects on Ion Chamber Measurements in a Co-60 beam”; J. Agnew, G. Budgell, S. Duane, F. O'Grady, R. Young; April 30, 10:45 – 11:45 a.m.;
  • Abstract: SP-0421: “Brachytherapy pelvic and MRI-Linac combination”; C.N. Nomden, A.A.C. de Leeuw, B.W. Raaymakers, J.J.W. Lagendijk, I.M. Jürgenliemk-Schulz; May 2, 8:45 – 10 a.m.;
  • Abstract: SP-0483: “MRI Linac: physics perspective”; B. Raaymakers, J.J.W. Lagendijk; May 2, 2:30 – 4 p.m.; and
  • Abstract: OC-0547: “Towards Portal Dosimetry for the MR-linac: back-projection algorithm in the presence of MRI scanner”; I. Torres Xirau, R. Rozendaal, I. Olaciregui-Ruiz, P. Gonzalez, U. van der Heide, J.J. Sonke, A. Mans; May 2, 4:45 – 5:45 p.m.


Elekta’s MR-linac is a work in progress and not available for sale or distribution.

For more information:

Related Content

Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...